Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Alexion shuffles management again

Paul Bonanos
May 23, 2017 6:59 PM UTC

Rare disease company Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said a handful of key executives are leaving the company. Among them are Chief Commercial Officer Carsten Thiel, CFO Dave Anderson and EVP and Head of R&D Martin Mackay.

Brian Goff is to replace Thiel, effective June 1. Goff was COO at Neurovance Inc., which Otsuka Pharmaceutical Co. Ltd. (Tokyo:4578) acquired this year. Prior to joining Neurovance, Goff was EVP and president of hematology at Baxalta Inc., which Shire plc (LSE:SHP; NASDAQ:SHPG) acquired. Alexion CEO Ludwig Hantson was Baxalta's president and CEO (see BioCentury Extra, March 27)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Alexion Pharmaceuticals Inc.